ProSomnus announced of its pilot study for the Company’s Next Generation Remote Patient Monitoring, RPM, device for Obstructive Sleep Apnea, OSA. Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. “This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory,” commented Len Liptak, Chief Executive Officer for ProSomnus Sleep Technologies. “Although we have more work to do in terms of FDA clearances, market access and commercialization, I am very proud that team ProSomnus is in the process of bringing this potentially life changing innovation to the millions of people suffering from OSA.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OSA:
- ProSomnus Faces Multiple Nasdaq Listing Compliance Issues
- ProSomnus announces FDA acceptance of 510(k) submission for EVO device
- ProSomnus to support OSA patients after Philips Respironics discontinuations
- ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
- ProSomnus initiated with a Buy at Alliance Global Partners